KR20090043618A - Nkg2d의 조절 - Google Patents
Nkg2d의 조절 Download PDFInfo
- Publication number
- KR20090043618A KR20090043618A KR1020097008488A KR20097008488A KR20090043618A KR 20090043618 A KR20090043618 A KR 20090043618A KR 1020097008488 A KR1020097008488 A KR 1020097008488A KR 20097008488 A KR20097008488 A KR 20097008488A KR 20090043618 A KR20090043618 A KR 20090043618A
- Authority
- KR
- South Korea
- Prior art keywords
- nkg2d
- cells
- mice
- rae
- antibody
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
Abstract
Description
NKG2D 내재화의 자극 (대조군에 비교시 NKG2D 표면 수준의 감소% 또는 소실율의 증가%) | NKG2D 활성화 (NKG2D-리간드 보유 세포에 노출한 후 NKG2D-보유 세포의 활성화 감소%) | NKG2D-발현 세포의 고갈 (대조군에 비교시 NKG2D 발현 세포의 감소%) |
20% | 30% | <5% |
20 | 50 | <5 |
20 | 70 | <5 |
20 | 90 | <5 |
20 | 70 | 10 |
20 | 70 | 20 |
20 | 70 | 30 |
20 | 70 | 50 |
40 | 30 | <5 |
40 | 50 | <5 |
40 | 70 | <5 |
40 | 90 | <5 |
40 | 70 | 10 |
40 | 70 | 20 |
40 | 70 | 30 |
40 | 70 | 50 |
90 | 30 | <5 |
90 | 50 | <5 |
90 | 70 | <5 |
90 | 90 | <5 |
90 | 70 | 10 |
90 | 70 | 20 |
90 | 70 | 30 |
90 | 70 | 50 |
Claims (25)
- NKG2D에 결합하는 항체 또는 항체 단편을 포함하며, 여기서 상기 항체 또는 항체 단편은 NKG2D+ T 세포 또는 NK 세포의 팽창을 상기 세포를 고갈시키지 않으면서 손상시킬 수 있는 것인, I형 당뇨병, 류마티스성 관절염, 다발성 경화증, 복강 질환, 염증성 장질환, 건선, 전신성 홍반성 루푸스, 하시모토 갑상선염, 중증 근육무력증, 길랑 바레 (Guillain-Barre) 증후군, 자가면역 포도막염, 원발성 담즙성 간경변, 자가면역 간염, 자가면역 용혈성 빈혈, 악성 빈혈, 자가면역 저혈소판증, 그레이브스병, 자가면역 난소염, 자가면역 고환염, 측두동맥염, 항-인지질 증후군, 베게너 육아종증, 베체트 (Behcet) 병, 공피증, 다발성 근염, 피부근육염, 강직척추염, 쇼그렌 (Sjogren) 증후군, 포진피부염, 심상성 천포창, 백반증, 건선 관절염, 골관절염, 스테로이드-내성 천식, 만성 폐쇄성 폐 질환, 아테롬성 동맥경화증 및 이식 거부반응으로 이루어진 군으로부터 선택된 질환을 치료 또는 예방하기 위한 의약.
- 제1항에 있어서, 상기 항체 또는 항체 단편이 세포-표면 NKG2D의 내재화 속도를 증가시키는 것인 의약.
- 제1항에 있어서, 상기 항체 또는 항체 단편이 NKG2D를 발현하는 백혈구의 리간드-유도 NKG2D 활성화를 감소시키는 것인 의약.
- 제1항에 있어서, 상기 항체 또는 항체 단편이 NKG2D-NKG2D 리간드 복합체를 통한 신호전달을 감소시키는 것인 의약.
- 제1항에 있어서, 상기 항체가 인간 또는 인간화 항체인 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 류마티스성 관절염을 치료 또는 예방하기 위한 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 다발성 경화증을 치료 또는 예방하기 위한 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 건선을 치료 또는 예방하기 위한 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 건선 관절염을 치료 또는 예방하기 위한 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 전신성 홍반성 루푸스를 치료 또는 예방하기 위한 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 염증성 장질환을 치료 또는 예방하기 위한 의약.
- 제11항에 있어서, 염증성 장질환이 크론병(Crohn's disease)인 의약.
- 제11항에 있어서, 염증성 장질환이 궤양성 대장염인 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 복강 질환을 치료 또는 예방하기 위한 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 하시모토 갑상선염, 쇼그렌 (Sjogren) 증후군, 베체트 (Bechet) 병, 베게너 육아종증, 강직척추염, 다발성 근염 및 피부근육염으로 이루어진 군으로부터 선택된 질환을 치료 또는 예방하기 위한 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, I형 당뇨병을 치료 또는 예방하기 위한 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 아테롬성 동맥경화증을 치료 또 는 예방하기 위한 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 비-스테로이드성 소염 약물 (NSAID), 질환 조절 항-류마티스 약물 (DMARD), 코르티코스테로이드, 항미생물제 및 생물학적 작용제로 이루어진 군으로부터 선택된 추가의 작용제 또는 이들의 조합을 더 포함하는 의약.
- 제18항에 있어서, 상기 DMARD가 메토트렉세이트 (methotrexate) 및 시클로스포린 A (Cyclosporine A)로 이루어진 군으로부터 선택되는 것인 의약.
- 제18항에 있어서, 상기 항미생물제가 항생제, 항바이러스제 및 항진균제로 이루어진 군으로부터 선택되는 것인 의약.
- 제20항에 있어서, 상기 항생제가 아미노살리실레이트인 의약.
- 제18항에 있어서, 상기 생물학적 작용제가 항체, 시토킨, 성장 인자, 항-TNF제 및 면역조절자로 이루어진 군으로부터 선택되는 것인 의약.
- 제22항에 있어서, 상기 항체가 항-종양괴사인자(TNF)-알파 항체 또는 항-IL-15 항체인 의약.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 이식 거부반응을 치료 또는 예방하기 위한 의약.
- 제24항에 있어서, 상기 이식 거부반응이 골수 이식 거부반응 또는 말초 혈액 줄기세포 이식 거부반응인 의약.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55991904P | 2004-04-05 | 2004-04-05 | |
US60/559,919 | 2004-04-05 | ||
US57624204P | 2004-06-01 | 2004-06-01 | |
US60/576,242 | 2004-06-01 | ||
US65967805P | 2005-03-07 | 2005-03-07 | |
US60/659,678 | 2005-03-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067023094A Division KR100912994B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090043618A true KR20090043618A (ko) | 2009-05-06 |
KR100919915B1 KR100919915B1 (ko) | 2009-10-06 |
Family
ID=35125614
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097008488A KR100919915B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
KR1020067023094A KR100912994B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
KR1020087022757A KR100895749B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067023094A KR100912994B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
KR1020087022757A KR100895749B1 (ko) | 2004-04-05 | 2005-04-05 | Nkg2d의 조절 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20080260727A1 (ko) |
EP (3) | EP1732588B1 (ko) |
JP (2) | JP4667451B2 (ko) |
KR (3) | KR100919915B1 (ko) |
CN (2) | CN102988959B (ko) |
AT (1) | ATE435656T1 (ko) |
AU (2) | AU2005231478C1 (ko) |
BR (1) | BRPI0509620A (ko) |
CA (1) | CA2563313C (ko) |
DE (1) | DE602005015302D1 (ko) |
DK (1) | DK1732588T3 (ko) |
ES (2) | ES2328597T3 (ko) |
MX (1) | MXPA06011553A (ko) |
PL (1) | PL1732588T3 (ko) |
WO (1) | WO2005097160A2 (ko) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7998481B2 (en) | 2004-04-05 | 2011-08-16 | The Regents Of The University Of California | Modulation of NKG2D for treating or preventing solid organ allograft rejection |
WO2005115517A2 (en) * | 2004-04-28 | 2005-12-08 | Joslin Diabetes Center, Inc. | Methods of treating diabetes |
EP1949107A1 (en) * | 2005-11-03 | 2008-07-30 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by nkg2d-positive cd4-positive cells |
WO2008014035A2 (en) * | 2006-07-25 | 2008-01-31 | The Regents Of The University Of California | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection |
CN101945893B (zh) † | 2007-12-14 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 抗人nkg2d抗体及其用途 |
US10865233B2 (en) | 2008-12-18 | 2020-12-15 | Dana-Farber Cancer Institute, Inc. | NKG2D-fc for immunotherapy |
MX2012001999A (es) * | 2009-08-17 | 2012-02-29 | Univ California | Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2. |
AU2011309689B2 (en) | 2010-09-28 | 2015-01-15 | Hadasit Medical Research Services & Development Ltd. | Compositions and methods for treatment of hematological malignancies |
KR101240206B1 (ko) | 2010-10-05 | 2013-03-06 | 고려대학교 산학협력단 | 자연살상 세포-매개 면역반응 억제용 조성물 |
EP2747785A4 (en) * | 2011-08-26 | 2015-04-15 | Univ California | METHOD AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES THROUGH NKG2D INHIBITION |
RS55822B1 (sr) * | 2011-09-30 | 2017-08-31 | Dana-Farber Cancer Institute Inc | Terapijski peptidi |
GB201218195D0 (en) * | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
PL3116902T3 (pl) * | 2014-03-11 | 2020-07-27 | Cellectis | Sposób wytwarzania limfocytów T kompatybilnych do przeszczepienia alogenicznego |
JP2018509148A (ja) * | 2015-03-11 | 2018-04-05 | セレクティスCellectis | 患者における持続性および/または生着を増加させるために同種t細胞を改変する方法 |
JP7186615B2 (ja) * | 2015-09-03 | 2022-12-09 | ザ ユーエイビー リサーチ ファウンデーション | 遺伝子操作された薬物耐性t細胞およびその使用方法 |
US10815290B2 (en) | 2015-11-10 | 2020-10-27 | Fred Hutchinson Cancer Research Center | NKG2D decoys |
EP3373970A4 (en) | 2015-11-13 | 2019-07-10 | Dana Farber Cancer Institute, Inc. | NKG2D IG FUSION PROTEIN FOR CANCER IMMUNOTHERAPY |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
CN110637083A (zh) * | 2017-03-20 | 2019-12-31 | 华盛顿大学 | 细胞及其使用和制备方法 |
EP3720950A1 (en) * | 2017-12-05 | 2020-10-14 | Celyad S.A. | Reducing fratricide of immune cells expressing nkg2d-based receptors |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
CN110713977B (zh) * | 2018-07-12 | 2022-05-27 | 上海赛傲生物技术有限公司 | 一种cd8 t细胞的培养扩增方法 |
US20220056092A1 (en) | 2018-12-11 | 2022-02-24 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
CA3132840A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
US20220267398A1 (en) | 2019-06-12 | 2022-08-25 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
AU2020290522A1 (en) | 2019-06-12 | 2022-01-20 | Obsidian Therapeutics, Inc. | CA2 compositions and methods for tunable regulation |
US20220323541A1 (en) * | 2019-08-13 | 2022-10-13 | Courier Therapeutics, Inc. | Orthopoxvirus major histocompatibility complex (mhc) class-i like protein (omcp) for treatment of autoimmune disease |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA89189A (en) | 1904-03-10 | 1904-09-13 | Frederick Palm | Valve |
CA95137A (en) | 1905-07-25 | 1905-09-19 | William E. Hingston | Envelope |
DK26743C (da) | 1918-10-14 | 1920-10-04 | Fabrikanter Og Forhandlere Af | Symaskine. |
DK63720C (da) | 1944-02-26 | 1945-07-23 | Jes Hansen Lauritzen | Anordning ved Maksimalafbrydere med en alt efter Overbelastningens Størrelse forsinket eller øjeblikkelig Afbrydelse af Forbrugsstrømmen. |
US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
EP0585257A4 (en) * | 1991-03-28 | 1995-02-22 | Univ Minnesota | DNA AND AMINO ACID SEQUENCE SPECIFIC TO NATURAL K KILLER CELLS. |
US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
EP1548118A2 (en) | 1994-06-10 | 2005-06-29 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
US5789244A (en) | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
CA2275141A1 (en) * | 1996-10-29 | 1998-05-07 | Thomas Spies | Cell stress regulated human mhc class i gene |
AU745409B2 (en) | 1997-01-29 | 2002-03-21 | Cornell Research Foundation Inc. | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
WO1999031241A1 (en) * | 1997-12-17 | 1999-06-24 | Immunex Corporation | Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
US6414218B1 (en) | 2000-01-18 | 2002-07-02 | The General Hospital Corporation | Mouse model for rheumatoid arthritis |
AU2001253255A1 (en) | 2000-04-07 | 2001-10-23 | Large Scale Biology Corporation | Compositions and methods for inhibiting gene expression |
US20040031066A9 (en) | 2001-01-18 | 2004-02-12 | Faustman Denise L. | Mouse model for rheumatoid arthritis |
US20040115198A1 (en) * | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
US20030095965A1 (en) * | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
US6821522B2 (en) * | 2001-05-31 | 2004-11-23 | The Regents Of The University Of California | Tumor Therapy |
US20030171280A1 (en) * | 2001-07-31 | 2003-09-11 | Soderstrom Karl Petter | Compositions and methods for modulation of immune responses |
CA2483343A1 (en) * | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
US7666417B2 (en) * | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
US7998481B2 (en) * | 2004-04-05 | 2011-08-16 | The Regents Of The University Of California | Modulation of NKG2D for treating or preventing solid organ allograft rejection |
-
2005
- 2005-04-05 BR BRPI0509620-0A patent/BRPI0509620A/pt not_active Application Discontinuation
- 2005-04-05 KR KR1020097008488A patent/KR100919915B1/ko active IP Right Grant
- 2005-04-05 WO PCT/US2005/011487 patent/WO2005097160A2/en active Application Filing
- 2005-04-05 CN CN201210340116.0A patent/CN102988959B/zh not_active Expired - Fee Related
- 2005-04-05 KR KR1020067023094A patent/KR100912994B1/ko active IP Right Grant
- 2005-04-05 CN CN2005800179326A patent/CN1984672B/zh not_active Expired - Fee Related
- 2005-04-05 AU AU2005231478A patent/AU2005231478C1/en not_active Ceased
- 2005-04-05 CA CA2563313A patent/CA2563313C/en not_active Expired - Fee Related
- 2005-04-05 MX MXPA06011553A patent/MXPA06011553A/es active IP Right Grant
- 2005-04-05 DE DE602005015302T patent/DE602005015302D1/de active Active
- 2005-04-05 DK DK05761976T patent/DK1732588T3/da active
- 2005-04-05 EP EP05761976A patent/EP1732588B1/en active Active
- 2005-04-05 AT AT05761976T patent/ATE435656T1/de not_active IP Right Cessation
- 2005-04-05 EP EP10183329.1A patent/EP2289534B1/en not_active Not-in-force
- 2005-04-05 JP JP2007507429A patent/JP4667451B2/ja not_active Expired - Fee Related
- 2005-04-05 PL PL05761976T patent/PL1732588T3/pl unknown
- 2005-04-05 ES ES05761976T patent/ES2328597T3/es active Active
- 2005-04-05 EP EP09008665.3A patent/EP2248529B1/en not_active Not-in-force
- 2005-04-05 KR KR1020087022757A patent/KR100895749B1/ko active IP Right Grant
- 2005-04-05 US US11/547,878 patent/US20080260727A1/en not_active Abandoned
- 2005-04-05 ES ES10183329.1T patent/ES2645026T3/es active Active
-
2009
- 2009-01-23 AU AU2009200269A patent/AU2009200269B2/en not_active Ceased
-
2010
- 2010-10-06 JP JP2010226316A patent/JP5693127B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-25 US US15/081,305 patent/US20160311906A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100919915B1 (ko) | Nkg2d의 조절 | |
EP2040730B1 (en) | Modulation of nkg2d in hbv patients | |
JP5936818B2 (ja) | 細胞傷害活性抗lag−3モノクローナル抗体および臓器移植拒絶および自己免疫疾患の治療または予防における該抗体の使用方法 | |
WO2008014035A2 (en) | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection | |
KR20230006477A (ko) | Hsp70을 표적화하는 모노클로날 항체 및 이의 치료학적 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120906 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20130910 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150908 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160909 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170912 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180906 Year of fee payment: 10 |